All the bases are covered, page-120

The revenue pipeline for HCT is pretty complex but I don't think you've taken the most important parts of the picture into account. We all know that share price isn't just a function of revenue vs MC.

HCT has massive potential which has already begun to be capitalized (although most did not appear in the last quarterly).

I do agree that speculative investors are growing tired of the wait but I absolutely disagree that we are at fair prices. You only have you look at the surge in interest at the last big announcement to see that there is interest waiting in the wings. I also agree that HCT isn't particularly good at shareholder relations but given where they are in their growth (the 'bloom phase' IMO), I would fear rather their resources are committed to manufacture and sales.

if this drops lower I will buy more - I think we are well below fair price and the first announcements on the past 4 weeks work (due very soon) will see a price surge. IMO